SAN

76.31

-1.56%↓

ARGX

694.2

-1.48%↓

SHL.DE

34.65

-1.17%↓

FRE

37.83

-1.46%↓

PHIA

23.18

-2.48%↓

SAN

76.31

-1.56%↓

ARGX

694.2

-1.48%↓

SHL.DE

34.65

-1.17%↓

FRE

37.83

-1.46%↓

PHIA

23.18

-2.48%↓

SAN

76.31

-1.56%↓

ARGX

694.2

-1.48%↓

SHL.DE

34.65

-1.17%↓

FRE

37.83

-1.46%↓

PHIA

23.18

-2.48%↓

SAN

76.31

-1.56%↓

ARGX

694.2

-1.48%↓

SHL.DE

34.65

-1.17%↓

FRE

37.83

-1.46%↓

PHIA

23.18

-2.48%↓

SAN

76.31

-1.56%↓

ARGX

694.2

-1.48%↓

SHL.DE

34.65

-1.17%↓

FRE

37.83

-1.46%↓

PHIA

23.18

-2.48%↓

Kodu・Aktsiate loetelu・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Suletud

SektorTervishoid

60.5 0.5

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

59.8

Max

60.85

Põhinäitajad
By Trading Economics
Sissetulek	-33M 9.5M
Müük	-66M 152M
P/E Sektori keskmine	24.576 49.701
Aktsiakasum	0.185
Kasumimarginaal	6.216
Töötajad	1,950
EBITDA	-45M 18M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+22.46% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	23. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-1.1B 3B
Eelmine avamishind	60
Eelmine sulgemishind	60.5

Uudiste sentiment

By Acuity

50%

159 / 345 Pingereas Healthcare

Laboratorios Farmaceuticos Rovi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. mai 2026, 08:24 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25. mai 2026, 21:22 UTC

Tulu

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25. mai 2026, 20:50 UTC

Market Talk

Tulu

Basic Materials Roundup: Market Talk

25. mai 2026, 16:20 UTC

Market Talk

Tulu

Basic Materials Roundup: Market Talk

25. mai 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25. mai 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25. mai 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25. mai 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25. mai 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25. mai 2026, 12:56 UTC

Market Talk

Tulu

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25. mai 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25. mai 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. mai 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25. mai 2026, 12:10 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Delivery Hero's Assets Look Strategic -- Market Talk

25. mai 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25. mai 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25. mai 2026, 10:05 UTC

Tulu

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25. mai 2026, 10:04 UTC

Tulu

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25. mai 2026, 10:03 UTC

Tulu

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25. mai 2026, 10:02 UTC

Tulu

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25. mai 2026, 10:01 UTC

Tulu

Tenaga Nasional 1Q Net Up 3.7% on Year

25. mai 2026, 10:00 UTC

Tulu

Tenaga Nasional 1Q Rev Up 6.6% on Year

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional 1Q EPS MYR0.1883

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional 1Q Rev MYR17.1B

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional 1Q Net MYR1.1B

25. mai 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25. mai 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25. mai 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25. mai 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Laboratorios Farmaceuticos Rovi SA Prognoos

Hinnasiht

By TipRanks

22.46% tõus

12 kuu keskmine prognoos

Keskmine 73.6 EUR 22.46%

Kõrge 83 EUR

Madal 64.2 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

159 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.